Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease
Hans Zischka, … , Karl H. Summer, Guido Kroemer
Hans Zischka, … , Karl H. Summer, Guido Kroemer
Published March 1, 2011
Citation Information: J Clin Invest. 2011;121(4):1508-1518. https://doi.org/10.1172/JCI45401.
View: Text | PDF
Research Article Hepatology

Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease

  • Text
  • PDF
Abstract

Wilson disease (WD) is a rare hereditary condition that is caused by a genetic defect in the copper-transporting ATPase ATP7B that results in hepatic copper accumulation and lethal liver failure. The present study focuses on the structural mitochondrial alterations that precede clinical symptoms in the livers of rats lacking Atp7b, an animal model for WD. Liver mitochondria from these Atp7b–/– rats contained enlarged cristae and widened intermembrane spaces, which coincided with a massive mitochondrial accumulation of copper. These changes, however, preceded detectable deficits in oxidative phosphorylation and biochemical signs of oxidative damage, suggesting that the ultrastructural modifications were not the result of oxidative stress imposed by copper-dependent Fenton chemistry. In a cell-free system containing a reducing dithiol agent, isolated mitochondria exposed to copper underwent modifications that were closely related to those observed in vivo. In this cell-free system, copper induced thiol modifications of three abundant mitochondrial membrane proteins, and this correlated with reversible intramitochondrial membrane crosslinking, which was also observed in liver mitochondria from Atp7b–/– rats. In vivo, copper-chelating agents reversed mitochondrial accumulation of copper, as well as signs of intra-mitochondrial membrane crosslinking, thereby preserving the functional and structural integrity of mitochondria. Together, these findings suggest that the mitochondrion constitutes a pivotal target of copper in WD.

Authors

Hans Zischka, Josef Lichtmannegger, Sabine Schmitt, Nora Jägemann, Sabine Schulz, Daniela Wartini, Luise Jennen, Christian Rust, Nathanael Larochette, Lorenzo Galluzzi, Veronique Chajes, Nathan Bandow, Valérie S. Gilles, Alan A. DiSpirito, Irene Esposito, Martin Goettlicher, Karl H. Summer, Guido Kroemer

×

Figure 8

Copper chelation therapies restore mitochondrial structure and function in Atp7b–/– rats.

Options: View larger image (or click on image) Download as PowerPoint
Copper chelation therapies restore mitochondrial structure and function ...
(A) The copper chelators D-PA and methanobactin decrease the copper content in liver compartments of Atp7b–/– animals (n = 4 and n = 3, respectively), preferentially in mitochondria. Copper amounts in liver subfractions are expressed relative to values from untreated clinically apparent Atp7b–/– animals (n = 4) set to hundred percent. Electron micrographs of liver mitochondria isolated from (B) a D-PA–treated and (C) a methanobactin-treated healthy Atp7b–/– animal (122 days and 120 days old, respectively; treatment started at day 85) and (D) an Atp7b–/– rat with initial liver damage (129 days old, D-PA treatment started at day 92). Whereas structural integrity was observed in B and C, slight enlargements of the intermembrane spaces were observed in D, indicating incomplete mitochondrial recovery (arrows). Scale bars: 0.5 μm. (E) D-PA and methanobactin treatments restore mitochondrial functional activity, as assessed by the succinate-driven respiratory control ratio (RCRS) in Atp7b–/– animals. A significantly higher RCRS was detected in mitochondria from Atp7b–/– animals that positively responded to these treatments versus clinically apparent Atp7b–/– rats.*P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts